Skip to main content
Erschienen in: European Radiology 11/2009

01.11.2009 | Hepatobiliary-Pancreas

Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: Is it possible to shorten the examination time?

verfasst von: Utaroh Motosugi, Tomoaki Ichikawa, Licht Tominaga, Hironobu Sou, Katsuhiro Sano, Shintaro Ichikawa, Tsutomu Araki

Erschienen in: European Radiology | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Aim: To examine if it is possible to shorten the examination time of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB)-enhanced MRI by omitting hepatocyte-phase images of 20-min delay time (Im-20) for detecting focal liver lesions. Materials and methods: Four hundred ninety-five malignant focal liver lesions observed on Im-20 in 265 patients were included. The hepatocyte phase was obtained 10 min (Im-10) and 20 min (Im-20) after Gd-EOB injection. Liver enhancement was evaluated using a 4-point scale [excellent/good/poor/non-diagnostic; visual liver-spleen contrast (V-LSC)] and a quantitative liver–spleen contrast ratio (Q-LSC). Two radiologists evaluated lesion conspicuity for assessing the sensitivity of lesion detection. As Im-20 was used as the standard of reference for the lesions, Im-20 artificially had 100% sensitivity. Results: The results showed that although sensitivities and Q-LSC significantly increased from Im-10 to Im-20 (sensitivity/mean Q-LSC: Im-5, 81%/1.4 Im-10, 96%/1.7: Im-20, 100%/1.9), the sensitivity of Im-10 achieved 100% (the same as Im-20) in patients with good/excellent V-LSC or Q-LSC of more than 1.5. On Im-10, 202 patients (77%) were assigned as having good/excellent V-LSC (78%), and 161 (61%) were assigned as having Q-LSC of more than 1.5. Conclusion: We concluded that Im-20 can be omitted in at least 61% of the patients.
Literatur
1.
Zurück zum Zitat Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67PubMed Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67PubMed
2.
Zurück zum Zitat Hammerstingl R, Huppertz A, Breuer J et al (2008) Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18:457–467CrossRefPubMed Hammerstingl R, Huppertz A, Breuer J et al (2008) Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18:457–467CrossRefPubMed
3.
Zurück zum Zitat Reimer P, Rummeny EJ, Shamsi K et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199:177–183PubMed Reimer P, Rummeny EJ, Shamsi K et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199:177–183PubMed
4.
Zurück zum Zitat Zech CJ, Herrmann KA, Reiser MF et al (2007) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 6:43–52CrossRefPubMed Zech CJ, Herrmann KA, Reiser MF et al (2007) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 6:43–52CrossRefPubMed
5.
Zurück zum Zitat Hamm B, Staks T, Muhler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792PubMed Hamm B, Staks T, Muhler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792PubMed
6.
Zurück zum Zitat Jung G, Breuer J, Poll LW et al (2006) Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 47:15–23CrossRefPubMed Jung G, Breuer J, Poll LW et al (2006) Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 47:15–23CrossRefPubMed
7.
Zurück zum Zitat Zech CJ, Grazioli L, Breuer J et al (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43:504–511CrossRefPubMed Zech CJ, Grazioli L, Breuer J et al (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43:504–511CrossRefPubMed
8.
Zurück zum Zitat Reimer P, Rummeny EJ, Daldrup HE et al (1997) Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 7:275–280CrossRefPubMed Reimer P, Rummeny EJ, Daldrup HE et al (1997) Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 7:275–280CrossRefPubMed
9.
Zurück zum Zitat World Medical Association Declaration of Helsinki (2001) Ethical principles for medical research involving human subjects. Bull World Health Organ 79:373–374 World Medical Association Declaration of Helsinki (2001) Ethical principles for medical research involving human subjects. Bull World Health Organ 79:373–374
10.
Zurück zum Zitat Stern W, Schick F, Kopp AF et al (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41:255–262CrossRefPubMed Stern W, Schick F, Kopp AF et al (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41:255–262CrossRefPubMed
11.
Zurück zum Zitat Brody JM, Schafer L, Tung GA et al (2005) Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid. J Magn Reson Imaging 21:391–397CrossRefPubMed Brody JM, Schafer L, Tung GA et al (2005) Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid. J Magn Reson Imaging 21:391–397CrossRefPubMed
12.
Zurück zum Zitat Shimizu J, Dono K, Gotoh M et al (1999) Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci 44:1330–1337CrossRefPubMed Shimizu J, Dono K, Gotoh M et al (1999) Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci 44:1330–1337CrossRefPubMed
13.
Zurück zum Zitat Saito K, Kotake F, Ito N et al (2005) Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 4:1–9CrossRefPubMed Saito K, Kotake F, Ito N et al (2005) Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 4:1–9CrossRefPubMed
14.
Zurück zum Zitat Tsuda N, Kato N, Murayama C et al (2004) Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Invest Radiol 39:80–88CrossRefPubMed Tsuda N, Kato N, Murayama C et al (2004) Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Invest Radiol 39:80–88CrossRefPubMed
15.
Zurück zum Zitat Bluemke DA, Sahani D, Amendola M et al (2005) Efficacy and safety of MR imaging with liver-specific contrast agent: US multicenter phase III study. Radiology 237:89–98CrossRefPubMed Bluemke DA, Sahani D, Amendola M et al (2005) Efficacy and safety of MR imaging with liver-specific contrast agent: US multicenter phase III study. Radiology 237:89–98CrossRefPubMed
16.
Zurück zum Zitat Ryeom HK, Kim SH, Kim JY et al (2004) Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol 5:231–239CrossRefPubMed Ryeom HK, Kim SH, Kim JY et al (2004) Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol 5:231–239CrossRefPubMed
17.
Zurück zum Zitat Tschirch FT, Struwe A, Petrowsky H et al (2008) Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 18:1577–1586CrossRefPubMed Tschirch FT, Struwe A, Petrowsky H et al (2008) Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 18:1577–1586CrossRefPubMed
Metadaten
Titel
Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: Is it possible to shorten the examination time?
verfasst von
Utaroh Motosugi
Tomoaki Ichikawa
Licht Tominaga
Hironobu Sou
Katsuhiro Sano
Shintaro Ichikawa
Tsutomu Araki
Publikationsdatum
01.11.2009
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 11/2009
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-009-1467-6

Weitere Artikel der Ausgabe 11/2009

European Radiology 11/2009 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.